Citations

Citations to this article as recorded by  

• GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025
  Thorsten Simon, Theresa Thole, Sveva Castelli, Beate Timmermann, Danny Jazmati, Rudolf Schwarz, Jörg Fuchs, Steven Warmann, Jochen Hubertus, Matthias Schmidt, Julian Rogasch, Friederike Körber, Christian Vokuhl, Jürgen Schäfer, Johannes Hubertus Schulte,
  Klinische Pädiatrie.2025; 237(03): 117.     CrossRef
• ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
  Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan L. Gabre, Agata Aniszewska, Anneli Strömberg, Mats Bemark, Michael N. Hall, Jimmy Van den Eynden, Bengt Hallbe
  Proceedings of the National Academy of Sciences.2024;[Epub]     CrossRef
• Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect
  Wararat Chiangjong, Jirawan Panachan, Sujitra Keadsanti, David S. Newburg, Ardythe L. Morrow, Suradej Hongeng, Somchai Chutipongtanate
  Nanomedicine: Nanotechnology, Biology and Medicine.2024; 60: 102760.     CrossRef
• Elevated Expression of LGR5 and WNT Signaling Factors in Neuroblastoma Cells With Acquired Drug Resistance
  John Clark-Corrigall, Svetlana Myssina, Martin Michaelis, Jindrich Cinatl, Shafiq Ahmed, Jane Carr-Wilkinson
  Cancer Investigation.2023; 41(2): 173.     CrossRef
• Computational intelligence analysis of high-risk neuroblastoma patient health records reveals time to maximum response as one of the most relevant factors for outcome prediction
  Davide Chicco, Riccardo Haupt, Alberto Garaventa, Paolo Uva, Roberto Luksch, Davide Cangelosi
  European Journal of Cancer.2023; 193: 113291.     CrossRef
• Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
  Aleksandra Wieczorek, Anna Zaniewska-Tekieli, Karoline Ehlert, Katarzyna Pawinska-Wasikowska, Walentyna Balwierz, Holger Lode
  Frontiers in Oncology.2023;[Epub]     CrossRef
• Adaptation of the Th-MYCN Mouse Model of Neuroblastoma for Evaluation of Disseminated Disease
  Seyed M. Rahavi, Maryam Aletaha, Ali Farrokhi, Amanda Lorentzian, Philipp F. Lange, Christopher A. Maxwell, Chinten James Lim, Gregor S. D. Reid
  International Journal of Molecular Sciences.2023; 24(15): 12071.     CrossRef
• Challenging diagnosis of Mycolicibacterium cosmeticum/canariasense infection: A case report and literature review
  Daniel Grupel, Orly Sagi, Israel Nissan, Rona Grossman, Motro Yair, Jacob Moran-Gilad, Dana Danino
  Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2023; 33: 100393.     CrossRef
• Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
  Aleksandra Wieczorek, Urszula Żebrowska, Marek Ussowicz, Agnieszka Sokół, Marzena Stypińska, Bożenna Dembowska-Bagińska, Katarzyna Pawińska-Wąsikowska, Walentyna Balwierz
  Journal of Clinical Medicine.2023; 12(16): 5252.     CrossRef
• Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors
  Kangwei Zhu, Yuren Xia, Xindi Tian, Yuchao He, Jun Zhou, Ruyu Han, Hua Guo, Tianqiang Song, Lu Chen, Xiangdong Tian
  Frontiers in Genetics.2023;[Epub]     CrossRef
• Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
  Juan Muñoz, Cristina Larrosa, Saray Chamorro, Sara Perez-Jaume, Margarida Simao, Nazaret Sanchez-Sierra, Amalia Varo, Maite Gorostegui, Alicia Castañeda, Moira Garraus, Sandra Lopez-Miralles, Jaume Mora
  Cancers.2023; 15(19): 4837.     CrossRef
• Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
  Diana Treis, Ganesh Umapathy, Susanne Fransson, Jikui Guan, Patricia Mendoza-García, Joachim T. Siaw, Sandra Wessman, Lena Gordon Murkes, Jakob J. E. Stenman, Anna Djos, Lotta H. M. Elfman, John Inge Johnsen, Bengt Hallberg, Ruth H. Palmer, Tommy Martinss
  JCO Precision Oncology.2022;[Epub]     CrossRef
• High-Risk Neuroblastoma: Poor Outcomes Despite Aggressive Multimodal Therapy
  Adil Abdelhamed Abbas, Alaa Mohammed Noor Samkari
  Current Cancer Therapy Reviews.2022; 18(1): 14.     CrossRef
• Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma
  Zijun Yan, Qiming Liu, Ziyang Cao, Jinxia Wang, Hongyang Zhang, Jiangbin Liu, Lin Zou
  Frontiers in Neuroinformatics.2022;[Epub]     CrossRef
• Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
  Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
  P. Berlanga, C. Pasqualini, U. Pötschger, C. Sangüesa, M.R. Castellani, A. Cañete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A. Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Caste
  European Journal of Cancer.2021; 144: 1.     CrossRef
• Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta
  Richa Jain, Amita Trehan, Prema Menon, Rakesh Kapoor, Nandita Kakkar, Srinivasan Radhika, Akshay Kumar Saxena, Bhagwant Rai Mittal, Neelam Varma, Ram Samujh, Deepak Bansal
  Pediatric Hematology and Oncology.2021; 38(4): 291.     CrossRef
• Neuroblastoma
  Christine Chung, Tom Boterberg, John Lucas, Joseph Panoff, Dominique Valteau‐Couanet, Barbara Hero, Rochelle Bagatell, Christine E. Hill‐Kayser
  Pediatric Blood & Cancer.2021;[Epub]     CrossRef
• Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan
  Yuya Saito, Mitsuyoshi Urashima, Yoshiyuki Takahashi, Atsushi Ogawa, Chikako Kiyotani, Yuki Yuza, Katsuyoshi Koh, Kenichiro Watanabe, Yoshiyuki Kosaka, Hiroaki Goto, Atsushi Kikuta, Keiko Okada, Yuhki Koga, Junya Fujimura, Masami Inoue, Atsushi Sato, Yosh
  Bone Marrow Transplantation.2021; 56(9): 2173.     CrossRef
• Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
  Paolo Uva, Maria Carla Bosco, Alessandra Eva, Massimo Conte, Alberto Garaventa, Loredana Amoroso, Davide Cangelosi
  Cancers.2021; 13(11): 2809.     CrossRef
• Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients
  T. Bauters, D. Heenen, K. Norga, A. Van Damme, A. Uyttebroeck, G. Laureys
  European Journal of Pediatrics.2021; 180(9): 3067.     CrossRef
• Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
  Neofit Spasov, Mariya Spasova, Stella Stabouli
  Case Reports in Pediatrics.2021; 2021: 1.     CrossRef
• Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
  Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey C. F. Chan, Geneviève Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schroeder, Cormac Owens, Ma
  Journal of Clinical Oncology.2021; 39(23): 2552.     CrossRef
• Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics
  Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml, Silvie Rimpelová
  Biology.2021; 10(9): 849.     CrossRef
• Extending the Applicability of In Ovo and Ex Ovo Chicken Chorioallantoic Membrane Assays to Study Cytostatic Activity in Neuroblastoma Cells
  Miguel Angel Merlos Rodrigo, Berta Casar, Hana Michalkova, Ana Maria Jimenez Jimenez, Zbynek Heger, Vojtech Adam
  Frontiers in Oncology.2021;[Epub]     CrossRef
• ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
  Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Tetteh Siaw, Arne Claeys, Jonatan L. Gabre, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
  Nature Communications.2021;[Epub]     CrossRef
• Association of PARP1 polymorphisms with response to chemotherapy in patients with high‐risk neuroblastoma
  Marianna Avitabile, Vito Alessandro Lasorsa, Sueva Cantalupo, Antonella Cardinale, Flora Cimmino, Annalaura Montella, Dalila Capasso, Riccardo Haupt, Loredana Amoroso, Alberto Garaventa, Alessandro Quattrone, Maria Valeria Corrias, Achille Iolascon, Mario
  Journal of Cellular and Molecular Medicine.2020; 24(7): 4072.     CrossRef
• Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
  Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Shifra Ash, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck-Pop
  Cancers.2020; 12(2): 309.     CrossRef
• Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
  F. Berthold, A. Faldum, A. Ernst, J. Boos, D. Dilloo, A. Eggert, M. Fischer, M. Frühwald, G. Henze, T. Klingebiel, C. Kratz, B. Kremens, B. Krug, I. Leuschner, M. Schmidt, R. Schmidt, R. Schumacher-Kuckelkorn, D. von Schweinitz, F.H. Schilling, J. Theisse
  Annals of Oncology.2020; 31(3): 422.     CrossRef
• Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
  S. L. George, V. Parmar, F. Lorenzi, L. V. Marshall, Y. Jamin, E. Poon, P. Angelini, L. Chesler
  Journal of Experimental & Clinical Cancer Research.2020;[Epub]     CrossRef
• Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study
  Keith Holmes, Ulrike Pötschger, Andrew D. J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E. Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean
  Journal of Clinical Oncology.2020; 38(25): 2902.     CrossRef
• Development of differentiation modulators and targeted agents for treating neuroblastoma
  Zegao Jin, Yang Lu, Yizhe Wu, Jinxin Che, Xiaowu Dong
  European Journal of Medicinal Chemistry.2020; 207: 112818.     CrossRef
• A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma
  Chiachen Chen, Michael S. Lan
  Cellular Signalling.2020; 76: 109785.     CrossRef
• Evolving treatments in high-risk neuroblastoma
  Abhinav Kumar, John P J Rocke, B Nirmal Kumar
  Expert Opinion on Orphan Drugs.2020; 8(12): 497.     CrossRef
• Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects
  Yao Wang, Jeffrey H. Stear, Ashleigh Swain, Xing Xu, Nicole S. Bryce, Michael Carnell, Irina B. Alieva, Vera B. Dugina, Timothy P. Cripe, Justine Stehn, Edna C. Hardeman, Peter W. Gunning
  Molecular Cancer Research.2020; 18(7): 1074.     CrossRef
• Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction
  Jasmin D. Haslbauer, Sarah Lindner, Gesine Bug, Eike Nagel, Valentina O. Puntmann
  Current Cardiovascular Imaging Reports.2019;[Epub]     CrossRef
• Therapy intensification in high-risk neuroblastoma patients with poor response to standard induction: experience of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology
  T. V. Shamanskaya, D. Y. Kachanov, A. V. Dumacheva, M. V. Teleshova, D. V. Shevtcov, T. V. Sergeeva, A. M. Syleimanova, R. A. Moiseenko, Y. N. Likar, . Kailash, S. R. Varfolomeeva
  Pediatric Hematology/Oncology and Immunopathology.2019; 18(4): 19.     CrossRef
• Molecular mechanisms and therapeutic targets in neuroblastoma
  John Inge Johnsen, Cecilia Dyberg, Susanne Fransson, Malin Wickström
  Pharmacological Research.2018; 131: 164.     CrossRef
• Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma
  Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias
  OncoImmunology.2018; 7(9): e1468953.     CrossRef
• Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
  Joshua Felgenhauer, Laura Tomino, Julia Selich-Anderson, Emily Bopp, Nilay Shah
  Neoplasia.2018; 20(10): 965.     CrossRef
• Prise en charge des neuroblastomes de haut risque : l’expérience du groupe européen SIOPEN
  Dominique Valteau-Couanet, Gudrun Schleiermacher, Sabine Sarnacki, Claudia Pasqualini
  Bulletin du Cancer.2018; 105(10): 918.     CrossRef
• Novel Therapies for Relapsed and Refractory Neuroblastoma
  Peter E. Zage
  Children.2018; 5(11): 148.     CrossRef
• Investigational drugs in phase II clinical trials for the treatment of neuroblastoma
  Loredana Amoroso, Riccardo Haupt, Alberto Garaventa, Mirco Ponzoni
  Expert Opinion on Investigational Drugs.2017; 26(11): 1281.     CrossRef